Saturday 17 October 2026
Export ADXN’s income statement to Excel — free account
Addex Therapeutics Ltd. Sponsored ADR
ADXN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 100.8%, EPS grew 25.7% and free cash flow fell 2.73%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.76
0.26
−8.61%
Follow ADXN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 4 | 3 | 2 | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(78.43) | (43.81) | (114.74) | (65.68) | (18.13) | (16.62) | — | — | — | — |
P/S ratio |
68.53 | 12.47 | 2.17 | 3.44 | 11.21 | 15.47 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(183.79) | (97.78) | (265.77) | (149.23) | (43.86) | (46.84) | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
5.79 | (0.36) | (5.44) | (1.77) | (1.09) | — | — | — | — | — |
P/Operating CF |
(10.13) | 73.32 | (6.94) | (1.51) | (10.92) | 58.52 | (7.03) | (7.03) | (7.03) | — |
P/B ratio |
1.20 | 0.52 | 3.06 | 0.99 | 1.93 | 3.82 | 1.30 | 1.30 | 1.30 | — |
Price to Tangible BV |
1.21 | 0.52 | 3.06 | 0.99 | 1.93 | 3.82 | 1.30 | 1.30 | 1.30 | — |
EV/Sales |
48.91 | 4.20 | (0.23) | (1.46) | 4.19 | 10.29 | 0.00 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.04 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(1.88) | (0.32) | 0.05 | 0.13 | (0.83) | (3.05) | 0.00 | 0.00 | 0.00 | — |
EV/FCF |
(1.88) | (0.32) | 0.05 | 0.13 | (0.83) | (3.04) | 0.00 | 0.00 | 0.00 | — |
Quick Ratio |
1.38 | 4.19 | 1.37 | 2.25 | 4.99 | 5.18 | 5.57 | 17.97 | 1.95 | 1.31 |
Current Ratio |
1.40 | 4.42 | 1.46 | 2.39 | 5.31 | 5.38 | 5.70 | 18.06 | 2.07 | 1.33 |
Net Debt/EBITDA |
0.58 | 1.34 | 0.39 | 0.34 | 1.35 | 1.58 | (11.69) | 29.31 | 0.80 | 0.44 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.05 | 0.26 | 0.09 | 0.14 | 0.33 | 0.00 | 0.00 | 0.62 | 0.00 |
Operating CF/Net income |
0.32 | (0.76) | 0.76 | 0.79 | 0.96 | 0.95 | 0.66 | (1.05) | 0.65 | 0.86 |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | 0.00 | (0.09) | (0.16) | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(180.70) | (782.42) | (30.34) | (65.50) | (246.23) | (18.82) | 73.10 | — | — | — |
| (96.99%) | 130.66% | (366.08%) | (184.19%) | (98.49%) | (65.47%) | (44.84%) | (8.11%) | (422.59%) | (389.80%) | |
| (81.98%) | 92.65% | (169.81%) | (130.77%) | (72.73%) | (118.36%) | 0.00% | 0.00% | (405.76%) | (129.31%) | |
ROIC |
(56.24%) | (27.18%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(1,396.32%) | 257.48% | (773.95%) | (453.44%) | (85.87%) | (80.69%) | (52.90%) | (4.13%) | (207.71%) | (739.47%) |
Average Days of Receivables |
244.01 | 14.00 | 24.97 | 106.96 | 20.63 | 6.91 | 15.97 | 14.87 | 221.89 | 0.00 |
Research and Development Expense of Revenue |
2,239.50% | 211.42% | 431.65% | 1,030.99% | 440.30% | 287.13% | 451.86% | 73.35% | 523.58% | 0.00% |
Selling, General and Administrative Expense of Revenue |
7,721.55% | 571.90% | 307.87% | 513.18% | 199.52% | 159.13% | 182.19% | 47.86% | 220.50% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
236.19% | 124.47% | 111.25% | 258.85% | 40.40% | 32.56% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.01 | 0.50 | 0.21 | 0.91 | 0.50 | 0.25 | 0.75 | 0.75 | 0.75 | — |
Graham Number |
0.00 | 52.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(120.76%) | 132.45% | (230.00%) | (435.29%) | (45.31%) | (22.76%) | (8.15%) | (8.15%) | (8.15%) | — |
Free Cash Flow Yield |
(37.99%) | (106.66%) | (228.41%) | (336.96%) | (45.07%) | (21.90%) | 0.00% | 0.00% | 0.00% | — |
Revenue per Share |
0.04 | 0.56 | 2.90 | 3.96 | 11.22 | 17.33 | 12.64 | 0.29 | 0.04 | 0.00 |
Operating CF per Share |
(2.93) | (7.46) | (14.38) | (45.75) | (56.57) | (58.41) | (44.86) | 0.08 | (0.17) | (0.23) |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | (0.12) | (0.29) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(2.93) | (7.46) | (14.39) | (45.75) | (56.69) | (58.70) | (44.86) | 0.08 | (0.17) | (0.23) |
Cash per Share |
2.21 | 4.64 | 6.95 | 19.36 | 78.81 | 89.66 | 147.78 | 1.83 | 0.20 | 0.12 |
Shareholders Equity per Share |
6.43 | 13.44 | 2.06 | 13.67 | 65.13 | 70.07 | 119.61 | 1.72 | 0.11 | 0.02 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.43 | 13.44 | 2.06 | 13.67 | 65.13 | 70.07 | 119.61 | 1.72 | 0.11 | 0.02 |
Free Cash Flow |
(2.62) | (6.11) | (8.91) | (17.23) | (16.12) | (13.05) | (9.87) | 1.76 | (2.18) | (2.65) |
Working Capital |
0.58 | 3.11 | 1.49 | 4.76 | 19.48 | 16.93 | 27.53 | 40.63 | 1.61 | 0.40 |
Capital Expenditures |
— | 0.00 | (0.01) | 0.00 | (0.03) | (0.06) | (0.03) | (0.01) | 0.00 | (0.01) |
Net Current Asset Value |
0.10 | 2.89 | 0.82 | 4.67 | 17.87 | 14.84 | 25.65 | 39.98 | 1.36 | 0.19 |
EV/EBIT |
0.00 | 0.00 | 0.04 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
11.33 | 227.31 | 13.52 | 7.86 | 4.82 | 5.51 | 0.58 | 0.33 | 5.43 | 1.49 |
Cash ROIC |
(33.90%) | (41.28%) | (159.63%) | (138.48%) | (39.39%) | (36.75%) | (16.78%) | 2.13% | (54.44%) | (165.22%) |
Accounts Receivable Turnover |
1.73 | 6.53 | 6.42 | 4.83 | 25.20 | 39.61 | 13.90 | 23.24 | 1.94 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
Inventory Turnover |
— | — | — | — | — | — | — | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9,474.44 |
Days of Inventory on Hand |
— | — | — | — | — | — | — | — | — | 0.00 |
Average Receivables |
0.02 | 0.07 | 0.28 | 0.31 | 0.13 | 0.10 | 0.20 | 0.29 | 0.26 | 0.26 |
Average Payables |
1.17 | 1.78 | 2.90 | 3.67 | 3.43 | 2.47 | 1.73 | 0.78 | 0.52 | 0.52 |
Average Assets |
9.91 | 8.65 | 6.92 | 16.67 | 23.09 | 11.59 | 0.00 | 0.00 | 0.82 | 2.39 |
Average Common Equity |
8.37 | 6.13 | 3.21 | 11.84 | 17.05 | 20.95 | 33.18 | 20.71 | 0.79 | 0.79 |
Columns are period end dates · fundamentals updated 30 Sep 2026